<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lovastatin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lovastatin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lovastatin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10823" href="/d/html/10823.html" rel="external">see "Lovastatin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12566" href="/d/html/12566.html" rel="external">see "Lovastatin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F55989382"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Statin Pregnancy Contraindication Update</span>
<span class="collapsible-date">July 2021</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">After a comprehensive review of all available data, the FDA is requesting all statin manufacturers to remove the contraindication in the prescribing information against using statins in pregnant patients. Although statin therapy should be discontinued in most pregnant patients, health care providers should consider the ongoing therapeutic needs of the individual patient, especially patients at very high risk of cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolemia or those with established cardiovascular disease. Additionally, breastfeeding is still not recommended in patients taking a statin; health care providers should determine whether it is better to temporarily stop statin therapy while breastfeeding or to continue statin therapy and not have the patient breastfeed. If ongoing statin treatment is necessary, infant formula and other alternatives are available. The FDA expects that removing the contraindication will enable health care providers and patients to make individual decisions about benefit and risk, especially for those at very high risk of heart attack or stroke.</p>
<p style="text-indent:0em;">Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy&amp;token=gxfbJKP%2B4jbjRRe1dXCv59qhZFmTmV73qmf%2FX%2BpwMjvINmMExoP9r7EcTZq6LKtsQ%2FwwXarvQCVId0NgjG9XzdICKlsdFJ73s%2FDoyuycmVDaUZCyqN73GrYM2%2BxRAta2zcZQxGheSuTnwZzuZPE4Up8XPwPhb7srLeP9xEjjtcA%3D&amp;TOPIC_ID=9575" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190412"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Altoprev</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867409"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Lovastatin [DSC];</li>
<li>GMD-Lovastatin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190451"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, HMG-CoA Reductase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F190417"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Lovastatin 40 to 80 mg/day is considered a moderate-intensity statin (generally reduces low-density lipoprotein-cholesterol [LDL-C] by ~30% to 49%). Lovastatin 20 mg/day is considered a low-intensity statin (reduces LDL-C &lt;30%). If LDL-C must be lowered ≥50%, select a high-intensity statin (atorvastatin or rosuvastatin). Assess response ~1 to 3 months after therapy initiation or dose adjustment and every 3 to 12 months thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use in conjunction with lifestyle modification (eg, diet, exercise). When initiating therapy and selecting dose intensity, consider age, baseline LDL-C, 10-year atherosclerotic cardiovascular disease (ASCVD) risk, risk-enhancing factors, potential adverse effects, and drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7278b27d-d997-480c-b845-59b986371f97">Heterozygous familial hyperlipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hyperlipidemia (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use of lovastatin should be limited to patients unable to tolerate a high-intensity statin (atorvastatin or rosuvastatin). Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients unable to tolerate high-intensity therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderate-intensity therapy:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: 40 to 80 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: 40 to 60 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4d76cb4-430b-418c-bf7b-688e7bf30bd0">Prevention of atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of atherosclerotic cardiovascular disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: If LDL-C goal (eg, percent reduction or absolute goal) is not met with the initial dose, may consider up-titration based on estimated 10-year ASCVD risk (see ACC/AHA ASCVD Risk Estimator Plus online), LDL-C response, and tolerability. If LDL-C goal is not met with maximally tolerated dose, consider switching to a high-intensity statin (atorvastatin or rosuvastatin); additional lipid-lowering therapy may be warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Primary prevention</i>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>without </i>d</b>
<b>iabetes, 40 to 75 years of age, and LDL-C 70 to 189 mg/dL:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk 5% to &lt;7.5%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest shared decision-making if ASCVD 10-year risk is 5% to 10%; in patients with a baseline LDL-C ≥160 mg/dL, statin therapy is usually recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 to 80 mg once daily with evening meal to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 40 to 60 mg once daily at bedtime to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% to &lt;20%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest initiating moderate-intensity statin therapy in most patients if ASCVD 10-year risk is &gt;10% to &lt;20% and LDL-C is &gt;100 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 to 80 mg once daily with evening meal to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 40 to 60 mg once daily at bedtime to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥20% (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of lovastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:14em;">Immediate release: 40 to 80 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:14em;">Extended release: 40 to 60 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>with</i> diabetes:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>40 to 75 years of age <i>without</i> additional ASCVD risk factors:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 to 80 mg once daily with evening meal to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 40 to 60 mg once daily at bedtime to reduce LDL-C by ~30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% or multiple ASCVD risk factors (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of lovastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-36031461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:14em;">Immediate release: 40 to 80 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:14em;">Extended release: 40 to 60 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients with LDL-C ≥190 mg/dL and 20 to 75 years of age (regardless of ASCVD risk estimate or coexisting diabetes mellitus) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Use of lovastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 to 80 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 40 to 60 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Secondary prevention</i></b>
<b>
<i> in patients with established atherosclerotic cardiovascular disease (eg, coronary heart disease, cerebrovascular disease [ischemic stroke or transient ischemic attack], peripheral arterial disease) (alternative agent)</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Use of lovastatin should be limited to patients unable to tolerate a high-intensity statin. Patients with high-risk ASCVD may require additional therapies to achieve LDL-C goal (eg, &lt;70 mg/dL or &lt;50 mg/dL if very high risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Immediate release: 40 to 80 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Extended release: 40 to 60 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991612"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline">CrCl &lt;30 mL/minute: Use with caution and carefully consider doses &gt;20 mg/day. </p></div>
<div class="block doha drugH1Div" id="F50988841"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F22889971"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe muscle symptoms or fatigue: </b>Promptly discontinue use; evaluate CPK, creatinine, and urinalysis for myoglobinuria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to moderate muscle symptoms: </b>Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution, resume the original or lower dose of lovastatin. If muscle symptoms recur, discontinue lovastatin use. After muscle symptom resolution, may then use a low dose of a different statin; gradually increase if tolerated. In the absence of continued statin use, if muscle symptoms or elevated CPK continues after 2 months, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F190418"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Immediate release: Refer to adult dosing; Extended release: Initial: Consider starting a lower dose of 20 mg once daily at bedtime and titrate as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F190431"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12566" href="/d/html/12566.html" rel="external">see "Lovastatin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a994b7e7-6ae7-48d9-8db4-a6a9aa9c4763">Dyslipidemia; prevention coronary artery disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia; prevention coronary artery disease (CAD): </b>Adolescents ≥18 years: Oral: Immediate release: Initial: 20 mg once daily with evening meal, then adjust at 4-week intervals; maximum daily dose: 80 mg/<b>day.</b>
<b>Note:</b> Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="355cd99a-0024-4930-8b95-6aee3ac5d71d">Heterozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hypercholesterolemia: Note:</b> Begin treatment if after adequate (eg, 6 month) trial of lifestyle/diet modifications the following are present: LDL-C ≥190 mg/dL or LDL-C remains ≥160 mg/dL with either a positive family history of premature cardiovascular disease or at least 1 high-level or 2 moderate-level risk factors. Females must be ≥1 year postmenarche (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents ≤17 years: Oral: Immediate release: Initial: 10 mg once daily with evening meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16140708','lexi-content-ref-8628597','lexi-content-ref-NHLBI.1','lexi-content-ref-9917116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16140708','lexi-content-ref-8628597','lexi-content-ref-NHLBI.1','lexi-content-ref-9917116'])">Ref</a></span>); if target LDL-C levels are not reached within 3 months, increase dose in 10 mg increments every 3 months until target LDL-C achieved; usual effective range: 10 to 40 mg once daily; maximum daily dose: 80 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16140708','lexi-content-ref-8628597','lexi-content-ref-NHLBI.1','lexi-content-ref-9917116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16140708','lexi-content-ref-8628597','lexi-content-ref-NHLBI.1','lexi-content-ref-9917116'])">Ref</a></span>). Lower initial doses or maximum daily doses may be necessary for some concomitant medications (eg, amiodarone, verapamil, danazol, diltiazem). <b>Note:</b> Children 8 to &lt;10 years of age are not typically treated unless severe primary hyperlipidemias and high-risk condition associated with high morbidity; data for the use of lovastatin in these younger patients is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: Muscle symptoms (potential myopathy):</b> Children ≥10 years and Adolescents: Discontinue use until symptoms can be evaluated; check creatine phosphokinase (CPK) level; based on experience in adult patients, also evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism; reduced renal or hepatic function; rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution (symptoms and any associated CPK abnormalities), resume the original or consider a lower dose of lovastatin and retitrate. If muscle symptoms recur, discontinue lovastatin use. After muscle symptom resolution, may then reinitiate a different statin at an initial low dose; gradually increase if tolerated. Based on experience in adult patients, if muscle symptoms or elevated CPK persists for 2 months in the absence of continued statin use, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1','lexi-content-ref-24222016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1','lexi-content-ref-24222016'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51128494"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: <b>Immediate release:</b> Children ≥10 years and Adolescents: Doses exceeding 20 mg/day should be carefully considered and implemented cautiously</p></div>
<div class="block dohp drugH1Div" id="F51128495"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in manufacturer's labeling (has not been studied); use is contraindicated in active liver disease or unexplained transaminase elevations.</p></div>
<div class="block adr drugH1Div" id="F190375"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (11% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (≥2x ULN:11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), constipation (3% to 4%), diarrhea (3%), flatulence (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (≥3x ULN: 2%; including increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1%), headache (7% to 8%), pain (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (2%), back pain (5%), muscle cramps (1%), myalgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (5%), sinusitis (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acid regurgitation, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lower extremity pain, myopathy, shoulder pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Changes in nails, changes of hair, cutaneous nodule, erythema multiforme, skin discoloration, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, increase in fasting plasma glucose, increased gamma-glutamyl transferase, loss of libido, thyroid dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dry mucous membranes, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (interstitial; Huang 2015), erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Elevated glycosylated hemoglobin, eosinophilia, hemolytic anemia, increased erythrocyte sedimentation rate, leukopenia, positive ANA titer, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, chronic active hepatitis, hepatic cirrhosis, hepatic failure, hepatic neoplasm, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, chills, cognitive dysfunction (including amnesia, confusion, memory impairment), cranial nerve disorder (including dysgeusia, facial paresis, impairment of extraocular movement), depression, malaise, peripheral nerve palsy, peripheral neuropathy, psychic disorder, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, dermatomyositis, lupus-like syndrome, polymyalgia rheumatica, rhabdomyolysis, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ophthalmoplegia, progression of cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, interstitial pulmonary disease</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F190392"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lovastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors [including boceprevir and telaprevir], telithromycin, cobicistat-containing products); pregnancy; breastfeeding</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use of cyclosporine</p></div>
<div class="block war drugH1Div" id="F190372"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia. If a patient develops diabetes mellitus during therapy, continue use of lovastatin and encourage patient to adhere to healthy lifestyle regimens (eg, heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight) (ACC/AHA [Grudy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endocrine effects: Reduced cholesterol synthesis as a result of therapy could theoretically lead to reduced adrenal or gonadal steroid hormone production; clinical trial data are inconsistent in regard to the effect on basal steroid hormone levels. Patients with signs/symptoms of endocrine dysfunction should be evaluated as clinically indicated; use caution with concomitant medications (eg, spironolactone, cimetidine, ketoconazole) that may reduce steroid hormone levels/activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Persistent elevations in serum transaminases have been reported; upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels. Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart lovastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy/rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, protease inhibitors), cyclosporine, fibric acid derivatives (eg, gemfibrozil), or niacin (doses ≥1 g/day); if concurrent use is warranted, consider lower starting and maintenance doses of lovastatin. Use caution in patients with inadequately treated hypothyroidism and those taking other drugs associated with myopathy (eg, colchicine), ≥65 years of age, and women; these patients are predisposed to myopathy. Immune-mediated necrotizing myopathy associated with HMG-CoA reductase inhibitor use has also been reported. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever. Discontinue therapy if markedly elevated CPK levels occur or if myopathy is diagnosed/suspected; consider treatment with immunosuppressants and additional neuromuscular and serologic testing. Prior to initiating a different HMG-CoA reductase inhibitor, consider risk of immune-mediated necrotizing myopathy; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: May rarely worsen or precipitate myasthenia gravis (MG); monitor for worsening MG if treatment is initiated (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; risk of myopathy is increased.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients with advanced age, these patients are predisposed to myopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>
<div class="block foc drugH1Div" id="F190384"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altoprev: 20 mg, 40 mg, 60 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p></div>
<div class="block geq drugH1Div" id="F190368"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F190394"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Altoprev Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $43.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $43.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $43.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lovastatin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.35 - $1.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $2.25 - $2.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $4.06 - $4.87</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867410"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block adm drugH1Div" id="F190389"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer IR tablet with the evening meal. Administer ER tablet at bedtime; do not cut, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.</p></div>
<div class="block admp drugH1Div" id="F52613196"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: </p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release tablets: Take with the evening meal. </p>
<p style="text-indent:-2em;margin-left:2em;">Extended release tablets: Take at bedtime; do not crush or chew.</p></div>
<div class="block use drugH1Div" id="F190388"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia, prevention of coronary artery disease:</b> Adjunct to dietary therapy in adolescent patients (10 to 17 years of age, females &gt;1 year postmenarche) with heterozygous familial hypercholesterolemia having low-density lipoprotein (LDL) &gt;189 mg/dL, <b>or</b> LDL &gt;160 mg/dL with positive family history of premature cardiovascular disease (CVD), <b>or</b> LDL &gt;160 mg/dL with the presence of at least 2 other CVD risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hyperlipidemia:</b> Adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in primary hypercholesterolemia (heterozygous familial and nonfamilial).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary prevention of atherosclerotic cardiovascular disease:</b> Reduce the risk of cardiovascular events in patients without symptomatic atherosclerotic cardiovascular disease (ASCVD) but who have multiple ASCVD risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary prevention of atherosclerotic cardiovascular disease:</b> Slow progression of coronary atherosclerosis in patients with ASCVD.</p></div>
<div class="block mst drugH1Div" id="F190459"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">HMG-CoA reductase inhibitors (when referred to as "statins") may be confused with nystatin.</p>
<p style="text-indent:-2em;margin-left:4em;">Lovastatin may be confused with atorvastatin, Leustatin, Livostin, Lotensin, nystatin, pitavastatin.</p>
<p style="text-indent:-2em;margin-left:4em;">Mevacor may be confused with Benicar, Lipitor.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lovacol [Chile and Finland] may be confused with Levatol brand name for penbutolol [U.S.]</p>
<p style="text-indent:-2em;margin-left:4em;">Lovastin [Malaysia, Poland, and Singapore] may be confused with Livostin brand name for levocabastine [multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Mevacor [US, Canada, and multiple international markets] may be confused with Mivacron brand name for mivacurium [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F190446"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F190377"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Lovastatin. Management: Consider using a non-interacting statin (pravastatin, pitavastatin) in patients on amiodarone. If combined, limit the lovastatin dose to 40 mg daily and monitor for lovastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: May increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Avoid use of bezafibrate and HMG-CoA reductase inhibitors (statins) unless strictly indicated due to the increased of muscle toxicity (including rhabdomyolysis). In patients who may be predisposed to myopathy, concomitant use is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Lovastatin. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Lovastatin may enhance the anticoagulant effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving danazol. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping statin (HMG-CoA reductase inhibitor) therapy prior to daptomycin. If daptomycin is used with a statin, creatine phosphokinase (CPK) monitoring could be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: May increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving diltiazem. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving dronedarone. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: May increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Lovastatin. Encorafenib may increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest possible starting statin dose and monitor patients closely for statin-related adverse effects (eg, muscle aches and pains) during coadministration with fostemsavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Lovastatin. Grapefruit Juice may increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Administer HMG-CoA reductase inhibitors (eg, statins) at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: May increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: May increase the serum concentration of Lovastatin. Management: Consider reducing lovastatin doses during concomitant treatment with lomitapide, and monitor for signs and symptoms of muscle toxicity.  Specific dosing recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pectin: May diminish the therapeutic effect of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (eg, brain, T-lymphocytes, testes, etc.). Management: Consider a lovastatin dose reduction if combined with ranolazine. An American Heart Association scientific statement recommends limiting lovastatin doses to 20 mg daily when used with ranolazine. Monitor closely for lovastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Lovastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease serum concentrations of the active metabolite(s) of HMG-CoA Reductase Inhibitors (Statins). Management: Consider avoiding the concomitant administration of St John's Wort with atorvastatin, lovastatin and simvastatin in order to avoid the potential for decreased effects statins.  If coadministered, monitor for decreased statin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: May increase the serum concentration of Lovastatin. Management: Limit lovastatin doses to 40 mg/day if coadministered with ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Lovastatin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving verapamil. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F190407"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases the bioavailability of lovastatin extended release tablets and increases the bioavailability of lovastatin immediate release tablets. Lovastatin serum concentrations may be increased if taken with grapefruit juice. Management: Avoid combination.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307998"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Lovastatin is contraindicated in females who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Adequate contraception is recommended if an HMG-CoA reductase inhibitor is required in females of reproductive potential. Females planning a pregnancy should discontinue the HMG-CoA reductase inhibitor 1 to 2 months prior to attempting to conceive (AHA/ACC [Grundy 2019]).</p></div>
<div class="block pri drugH1Div" id="F190395"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lovastatin is contraindicated in pregnant females.</p>
<p style="text-indent:0em;margin-top:2em;">There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Lovastatin should be discontinued immediately if an unplanned pregnancy occurs during treatment.</p></div>
<div class="block brc drugH1Div" id="F16609516"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if lovastatin is present in breast milk. Due to the potential for serious adverse reactions in a breastfed infant, use while breastfeeding is contraindicated by the manufacturer.</p></div>
<div class="block dic drugH1Div" id="F190396"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy. Avoid intake of grapefruit juice; may increase toxicity. Immediate release tablet should be taken with the evening meal.</p>
<p style="text-indent:0em;margin-top:2em;">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi  2008; Smith  2003).</p></div>
<div class="block mop drugH1Div" id="F190382"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Grundy 2019]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Lipid profile (fasting or nonfasting) before initiating treatment. Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (AST and ALT); measure AST, ALT, total bilirubin, and alkaline phosphatase if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>
<p style="text-indent:-2em;margin-left:4em;">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Manufacturer's labeling:</b> Consider neuromuscular and serologic testing if immune-mediated necrotizing myopathy is suspected.</p></div>
<div class="block pha drugH1Div" id="F190371"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lovastatin acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus  2002; Ray  2005).</p></div>
<div class="block phk drugH1Div" id="F190391"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: LDL-cholesterol reductions: 3 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 30% absorbed but less than 5% reaches the systemic circulation due to an extensive first-pass effect; increased with extended release tablets when taken in the fasting state</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;95% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; extensive first-pass effect; hydrolyzed to β-hydroxyacid (active) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Increased with extended release tablets </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1.1-1.7 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release: 2-4 hours; extended release: 12-14 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~80% to 85%); urine (10%)</p></div>
<div class="block phksp drugH1Div" id="F51153991"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma concentrations of total inhibitors are increased 2-fold in severe renal insufficiency (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: <b></b> The mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% in elderly patients 70 to 78 years of age compared with patients 18 to 30 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190397"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mevacor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hipovastin | Loriter | Lovastatin ilab | Mevlor | Sivlor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lovastatin hexal | Lovastatin stada artzneimittel | Mevacor</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aztatin | Lovatin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Holetar | Lipopres | Mevacor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lipoclin | Lovastatina | Lovasterol | Lovaton | Mevacor | Mevalip | Neolipid | Reducol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Colevix | Hiposterol | Lispor | Lovacol | Lovalip | Lovastatina | Mevacor | Sanelor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai le ting | Hai li | Le fu xin | Luo hua ning | Mei xin jie | Xin lu | Xue qing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Closterol | Colevix | Corastan | Dislipin | Lincil | Lovastan | Lovastatina | Lovasterol | Mevacor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo lovastatin | Holetar | Lovacard | Medostatin | Mevacor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lova | Lovabeta | Lovadura | Lovagamma | Lovahexal | Lovastatin Actavis | Lovastatin al | Lovastatin CT | Lovastatin Isis | Lovastatin ratiopharm | Lovastatin saar | Lovastatin Stada | Lovastatin Teva | Mevacor | Mevinacor</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Lovastatin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hexaltina | Lipostatin | Lovastatina | Mevinacor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lipivas | Lovasin | Lovastatina | Lovastin | Rovacor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mevacor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cholilysis | Lipdip | Lovastan | Lovastmed | Lowchol | Sabastatin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aterkey | Colesvir | Liposcler | Lovastatina aphar | Lovastatina bexal | Lovastatina centrum | Lovastatina cinfa | Lovastatina combinopharm | Lovastatina cuve | Lovastatina Davur | Lovastatina grapa | Lovastatina juventus | Lovastatina kern | Lovastatina lareq | Lovastatina lasa | Lovastatina mabo | Lovastatina merck | Lovastatina normon | Lovastatina Pensa | Lovastatina Sandoz | Lovastatina vir | Mevacor | Mevasterol | Nergadan | Taucor</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Medostatin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lovacol | Lovastatiini ennapharma | Lovastatin alternova | Lovastatin hexal | Lovastatin ratiopharm | Lovastatin sandoz | Lovastatin Stada | Mevacor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Liferzit | Lipidless | Lostin | Lovadrug | Lovapen | Lovasten | Lovatex | Lovatop | Lowlipid | Medovascin | Mevacor | Mevastin | Mevinol | Misodomin | Nabicortin | Terveson | Viking</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo lovastatin | Cysin | Lofacol | Lomar | Lovatin | Lozutin | Medostatin | Mevacor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mevacor | Stoplip</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Belvas | Cholestra | Cholvastin | Justin | Lipovas | Lofacol | Lotyn | Lovatrol | Paschol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lovalip</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aztatin | Elstatin | Elstin | Favolip | Lestric | Lipdip | Lipistat | Lochol | Lostatin | Lotin | Lova | Lovacard | Lovadac | Lovalip | Lovameg | Lovastat | Lovastrol | Lovatin | Lovex | Pro-hdl | Recol | Rovacor | Satin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lovastatina doc | Lovastatina eg | Lovastatina mylan pharma | Lovastatina provvisoria | Lovastatina teva | Lovinacor | Rextat | Tavacor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lostin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arbatin | Birotin | Cholvatin | Dovastin | Loctin | Lostatin | Lostin | Lovaclin | Lovacol | Lovaitin | Lovalord | Lovarex | Lovast | Lovastin | Lovatadin | Lovatone | Lowtin | Mevacor | Meverstin | Ovasta | Rostatin | Vaslotin | Vasterol | Vastin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mevacor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aterkey</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Holetar | Mevacor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lovahexal | Mevacor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lovahexal | Lovasterol | Mevacor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Casbame | Dilucid | Liperol | Mevacor | Sidevar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo lovastatin | Ellanco | Lestric | Loactin | Lostatin | Lovacard | Lovarem | Lovastin | Lovatin | Medostatin | Mevacor | Rovacor | Sunocor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lucovitaal rode gist rijst</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Liprox | Lovabeta | Lovastatin ratiopharm | Mevacor</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Colevastina | Liporedux | Lostatin | Lovacol | Lovastatina | Lowcol | Mevacor | Rovacor</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cholescor | Clolip | Colostin | Cutcol | Hypolip | Lestin | Lo-lipid | Lovacor | Lovastat | Lovax | Lovestan | Mevacor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anlostin | Apo-lova | Liprox | Lovastatinum | Lovasterol | Lovastin | Lowastatyna | Mevacor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Altoprev | Mevacor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Flozul | Lipdaune | Lipus | Lovastatina | Lovastatina azevedos | Lovastatina germed | Lovastatina mepha | Lovastatina Sandoz | Mevinacor | Mevlor | Tecnolip</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lovacol | Lovastatina genfar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Medostatin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lovastatina arena</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apextatin | Cardiostatin | Choletar | Holetar | Lovastatin vero | Medostatin | Mevacor | Rovacor | Vero lovastatin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo lovastatin | Elstatin | Lochol | Lostatin | Lovastin | Lovatin | Medostatin | Rovacor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Artein | Holetar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Medostatin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lovastatine Cinfa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lovakor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo lovastatin | Asacor | Celeton | Clatin | Cysin | Delipic | Leslipid | Lova | Lovacor | Lovast | Lovasta | Lovastin | Lovatin | Lozutin | Medostatin | Melova | Mevacor | Rodatin | Sancos | Trunshay | Ulova</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lovameg | Mevacor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Hipovastin | Lovestol | Mevlor | Normosterol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dislipin | Levistan | Lostatin | Lovanil | Lovastatina | Mevacor</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Vastanic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lovachol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lovacard | Lovalip</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Covis.1">
<a name="Covis.1"></a>Altoprev (lovastatin) [prescribing information]. Zug, Switzerland: Covis Pharma; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11345978">
<a name="11345978"></a>American Academy of Pediatrics Committee on Nutrition, “Cholesterol in Childhood,” <i>Pediatrics</i>, 1998, 101(1 Pt 1):141-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/11345978/pubmed" id="11345978" target="_blank">11345978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1538956">
<a name="1538956"></a>American Academy of Pediatrics, “National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,” <i>Pediatrics</i>, 1992, 89(3 Pt 2):525-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/1538956/pubmed" id="1538956" target="_blank">1538956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline [published correction appears in: <i>J Clin Endocrinol Metab</i>. 2015;100(12):4685]. <i>J Clin Endocrinol Metab</i>. 2012;97(9):2969-2989. doi: 10.1210/jc.2011-3213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27838723">
<a name="27838723"></a>Bibbins-Domingo K, Grossman DC, Curry, SJ, et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2016;316(19):1997-2007. doi: 10.1001/jama.2016.15450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/27838723/pubmed" id="27838723" target="_blank">27838723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDA.1">
<a name="CDA.1"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. <i>Can J Diabetes. </i>2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22870499">
<a name="22870499"></a>Castro C, Gourley M. Diagnosis and treatment of inflammatory myopathy: issues and management. <i>Ther Adv Musculoskelet Dis.</i> 2012;4(2):111-120. doi: 10.1177/1759720X11425092.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/22870499/pubmed" id="22870499" target="_blank">22870499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16140708">
<a name="16140708"></a>Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. <i>Pediatrics</i>. 2005;116(3):682-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/16140708/pubmed" id="16140708" target="_blank">16140708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596007">
<a name="18596007"></a>Daniels SR, Greer FR, and Committee on Nutrition, "Lipid Screening and Cardiovascular Health in Childhood," <i>Pediatrics</i>, 2008, 122(1):198-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/18596007/pubmed" id="18596007" target="_blank">18596007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12398573">
<a name="12398573"></a>De Denus S, Spinler SA. Early statin therapy for acute coronary syndromes. <i>Ann Pharmacother</i>. 2002;36(11):1749-1758. doi: 10.1345/aph.1A413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12398573/pubmed" id="12398573" target="_blank">12398573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10573325">
<a name="10573325"></a>Duplaga BA, “Treatment of Childhood Hypercholesterolemia With HMG-CoA Reductase Inhibitors,” <i>Ann Pharmacother</i>, 1999, 33(11):1224-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/10573325/pubmed" id="10573325" target="_blank">10573325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368702">
<a name="11368702"></a>“Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” <i>JAMA</i>, 2001, 285(19):2486-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/11368702/pubmed" id="11368702" target="_blank">11368702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18689579">
<a name="18689579"></a>Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. <i>Chest</i>. 2008;134(4):824-830. doi: 10.1378/chest.08-0943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/18689579/pubmed" id="18689579" target="_blank">18689579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in: <i>Circulation</i>. 2014;129(16):e463]. <i>Circulation</i>. 2012;126(25):e354-e471. doi: 10.1161/CIR.0b013e318277d6a0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333. doi: 10.1161/CIR.0000000000000106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136683">
<a name="11136683"></a>Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. <i>Circulation</i>. 2001;103(1):38-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/11136683/pubmed" id="11136683" target="_blank">11136683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23032657">
<a name="23032657"></a>Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. <i>Ann Pharmacother</i>. 2012;46(10):1419-1424. doi: 10.1345/aph.1R202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/23032657/pubmed" id="23032657" target="_blank">23032657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15249516">
<a name="15249516"></a>Grundy SM, Cleeman JI, Merz CN, et al, “Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,” <i>Circulation</i>, 2004, 110(2):227-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/15249516/pubmed" id="15249516" target="_blank">15249516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15297292">
<a name="15297292"></a>Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Arterioscler Thromb Vasc Biol</i>. 2004;24(8):e149-e161. doi: 10.1161/01.ATV.0000133317.49796.0E.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/15297292/pubmed" id="15297292" target="_blank">15297292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28531241">
<a name="28531241"></a>Han BH, Sutin D, Williamson JD, et al; ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT randomized clinical trial. <i>JAMA Intern Med</i>. 2017;177(7):955-965. doi: 10.1001/jamainternmed.2017.1442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/28531241/pubmed" id="28531241" target="_blank">28531241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12114036">
<a name="12114036"></a>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. <i>Lancet</i>. 2002;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12114036/pubmed" id="12114036" target="_blank">12114036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11914253">
<a name="11914253"></a>Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. <i>Circulation</i>. 2002;105(12):1446-1452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/11914253/pubmed" id="11914253" target="_blank">11914253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26184102">
<a name="26184102"></a>Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232. doi: 10.1159/000431185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/26184102/pubmed" id="26184102" target="_blank">26184102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911072">
<a name="25911072"></a>Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/25911072/pubmed" id="25911072" target="_blank">25911072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi: 10.1161/CIR.0000000000000041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25679302">
<a name="25679302"></a>Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/25679302/pubmed" id="25679302" target="_blank">25679302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8628597">
<a name="8628597"></a>Lambert M, Lupien PJ, Gagne C, et al, “Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin. Canadian Lovastatin in Children Study Group,” <i>Pediatrics</i>, 1996, 97(5):619-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/8628597/pubmed" id="8628597" target="_blank">8628597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637891">
<a name="18637891"></a>Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574. doi: 10.1111/j.1365-2125.2008.03224.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/18637891/pubmed" id="18637891" target="_blank">18637891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15755765">
<a name="15755765"></a>LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>N Engl J Med</i>. 2005;352(14):1425-1435. doi: 10.1056/NEJMoa050461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/15755765/pubmed" id="15755765" target="_blank">15755765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22480340">
<a name="22480340"></a>Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. <i>Drugs</i>. 2012;72(6):773-788. doi: 10.2165/11632010-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/22480340/pubmed" id="22480340" target="_blank">22480340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17513620">
<a name="17513620"></a>Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. <i>Anesth Analg</i>. 2007;104(6):1326-1333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/17513620/pubmed" id="17513620" target="_blank">17513620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Lovastatin [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BluePoint.1">
<a name="BluePoint.1"></a>Lovastatin tablet [prescribing information]. Princeton, NJ; BluePoint Laboratories; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPharma.1">
<a name="AAPharma.1"></a>Lovastatin tablets [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," <i>Circulation</i>, 2007, 115(14):1948-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease [published correction appears in <i>Can J Cardiol</i>. 2006;22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Mevacor (lovastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301631">
<a name="29301631"></a>Mortensen MB, Falk E. Primary prevention with statins in the elderly. <i>J Am Coll Cardiol</i>. 2018;71(1):85-94. doi: 10.1016/j.jacc.2017.10.080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/29301631/pubmed" id="29301631" target="_blank">29301631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute, "Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," <i>Clinical Practice Guidelines</i>, 2011, National Institutes of Health. Available at http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22091490">
<a name="22091490"></a>Newson RS, Felix JF, Heeringa J, Hofman A, Witteman JC, Tiemeier H. Association between serum cholesterol and noncardiovascular mortality in older age. <i>J Am Geriatr Soc</i>. 2011;59(10):1779-1785. doi: 10.1111/j.1532-5415.2011.03593.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/22091490/pubmed" id="22091490" target="_blank">22091490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12215610">
<a name="12215610"></a>Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. <i>Stroke</i>. 2002;33(9):2337-2341. http://stroke.ahajournals.org/cgi/content/short/33/9/2337
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12215610/pubmed" id="12215610" target="_blank">12215610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12551878">
<a name="12551878"></a>Pearson TA, Mensah GA, Alexander RW, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. <i>Circulation</i>. 2003;107(3):499-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12551878/pubmed" id="12551878" target="_blank">12551878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8615304">
<a name="8615304"></a>Phillips BG, Yim JM, Brown EJ Jr, et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. <i>Am Heart J</i>. 1996;131(5):872-878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/8615304/pubmed" id="8615304" target="_blank">8615304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pignone.1">
<a name="Pignone.1"></a>Pignone M. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12695283">
<a name="12695283"></a>Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. <i>Circulation</i>. 2003;107(14):1848-1851. doi: 10.1161/01.CIR.0000066286.15621.98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12695283/pubmed" id="12695283" target="_blank">12695283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16226165">
<a name="16226165"></a>Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433. doi: 10.1016/j.jacc.2005.05.086.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/16226165/pubmed" id="16226165" target="_blank">16226165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18997196">
<a name="18997196"></a>Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <i>N Engl J Med</i>. 2008;359(21):2195-2207. doi: 10.1056/NEJMoa0807646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/18997196/pubmed" id="18997196" target="_blank">18997196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.1">
<a name="Rosenson.1"></a>Rosenson RS. Familial hypercholesterolemia in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.2">
<a name="Rosenson.2"></a>Rosenson RS, Hayward RA, Lopez-Sendon J. Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686036">
<a name="12686036"></a>Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet</i>. 2003;361(9364):1149-1158. doi: 10.1016/S0140-6736(03)12948-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12686036/pubmed" id="12686036" target="_blank">12686036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12457784">
<a name="12457784"></a>Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. <i>Lancet</i>. 2002;360(9346):1623-1630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/12457784/pubmed" id="12457784" target="_blank">12457784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7566020">
<a name="7566020"></a>Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. <i>N Engl J Med</i>. 1995;333(20):1301-1307. doi: 10.1056/NEJM199511163332001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/7566020/pubmed" id="7566020" target="_blank">7566020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14696880">
<a name="14696880"></a>Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267. doi: 10.1097/01.SMJ.0000100117.79718.DC.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/14696880/pubmed" id="14696880" target="_blank">14696880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9917116">
<a name="9917116"></a>Stein EA, Illingworth DR, Kwiterovich PO Jr, et al, “Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial,” <i>JAMA</i>, 1999, 281(2):137-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/9917116/pubmed" id="9917116" target="_blank">9917116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25 Suppl 2):S1-45. doi:10.1161/01.cir.0000437738.63853.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11831543">
<a name="11831543"></a>Sun JX, Niecestro R, Phillips G, Shen J, Lukacsko P, Friedhoff L. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. <i>J Clin Pharmacol</i>. 2002;42(2):198-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/11831543/pubmed" id="11831543" target="_blank">11831543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>“Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323134">
<a name="24323134"></a>Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. <i>Ann Intern Med</i>. 2014;160(3):182. doi: 10.7326/M13-2453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/24323134/pubmed" id="24323134" target="_blank">24323134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28685504">
<a name="28685504"></a>Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. <i>Cochrane Database Syst Rev</i>. 2017;7:CD006401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lovastatin-drug-information/abstract-text/28685504/pubmed" id="28685504" target="_blank">28685504</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9575 Version 560.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
